Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
Reid W. Merryman(Harvard University), Alex F. Herrera(City of Hope), Jakub Svoboda(UPMC Hillman Cancer Center), Ryan C. Lynch(Seattle Cancer Care Alliance), Jonathon B. Cohen(Emory University), Kevin A. David(Rutgers, The State University of New Jersey), Robert Redd(Harvard University), Kami J. Maddocks(The Ohio State University), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Yi‐Bin Chen(Massachusetts General Hospital), Hatcher J. Ballard(University of Pennsylvania), Anurag K. Singh(University Medical Center), Michael Byrne(Vanderbilt University Medical Center), Vincent T. Ho, David A. Bond(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Joseph P. McGuirk(University of Kansas Medical Center), Philippe Armand(Harvard University), Ranjana H. Advani(Stanford Medicine), Matthew J. Frigault(Harvard University), Jason T. Romancik(Emory University), Justin Darrah(Cedars-Sinai Medical Center), Stephen D. Smith(Seattle Cancer Care Alliance), Uttam K. Rao(Sarah Cannon), Mansi Shah(University of North Carolina at Chapel Hill), Maryam Rahimian(Beth Israel Deaconess Medical Center), Michael A. Spinner(Stanford Medicine)
Cited by 2
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k